Recently a combination package containing 4 self explaining one week blisters, each with one tablet of 70mg alendronate and 7 capsules of 1 mcg alfacalcidol, was introduced primarily Dolutegravir
in Germany (Tevabone? -TEVA/AWD.pharma). Methods: 825 practicing physicians all over Germany recruited 2579 patients for a 12 week phase 4 observational trial with the above new combination pack. 92% were women; the average age was 74 years. 55% had a history of falls. Prevalent vert. and non-vert. fractures were documented in 62% and 63% of the patients resp. and a creatinine clearance below 65ml/min was documented in 65%. Main outcome parameters were CRT (Chair Rising Test) and TUG (Timed Up and Go test) and back pain at onset and after 3 months. Results: The percentage of patients able to perform the CRT within 10 sec. increased from 26% at onset to 43% after 3 months (increase 63%, p<0.001) while the successful performance within 10 sec of TUG increased by 54% (p<0.001). The average overall improvement of CRT was 2.3 sec. and of TUG amounted to 2.4 sec. It was shown in another recently published study that a mean increase of 2.6 sec. in the performance of TUG results in a 24% increased risk for non-vert. fractures (2). Mean back pain measured by the Visual Analogue Scale (VAS 0 - 10) decreased significantly from 5.9 to 3.5 (p<0,001). Conclusion: With the new combined regimen of alfacalcidol and alendronate highly significant <a href="http://www.selleckchem.com/products/z-vad-fmk.html
">Z-VAD-FMK cost ameliorations in back pain, CRT and TUG could be reached already after 3 months. This may contribute to the previously shown significant effects on falls and fractures with the same regimen during a long-term trial (1). 1. Ringe JD et al.: Rheumatol Int. 2007;27:425-34 2. Zhu K et al.: J Bone Miner Res 2008:23;119 Disclosures: Johann Diederich Ringe, TEVA/AWD.pharma, 5 This study received funding from: TEVA/AWD.pharma SU0391 Safety and Efficacy of Risedronate Galunisertib molecular weight
in Osteoporosis Patients with Diabetes Mellitus, Hypertension or Dislipidemia -A Pooled Analysis of Three Clinical Trials in Japan.Ryo Okazaki*1, Daisuke Inoue1, Yoshiki Nishizawa2, Ryoichi Muraoka3, Toshitsugu Sugimoto4. 1Teikyo University Chiba Medical Center, Japan, 2Osaka City University Medical School, Japan, 3Ajinomoto Phamaceuticals Co, Ltd., Japan, 4Shimane University School of Medicine, Japan The number of patients with osteoporosis who also have metabolic syndrome has been increasing in developed countries. Risedronate(RIS) has been shown to inhibit osteoporotic fractures and widely used in the world. However, it is unknown whether this agent is equally efficacious in patients with metabolic syndrome. Thus, we did post-hoc analyses of RIS Japanese phase III trials to see whether the presence of diabetes mellitus(DM), hypertension(HTN) or dyslipidemia(HL) affect its efficacy and safety.